Drug Profile
Natural killer cell therapy - Takara Bio
Alternative Names: Lymphokine-activated-killer-cells-Takara-Bio; NK cell therapy - Takara BioLatest Information Update: 10 Oct 2021
Price :
$50
*
At a glance
- Originator Takara Bio
- Developer Kyoto Prefectural University of Medicine; Takara Bio
- Class Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal cancer
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Inoperable/Unresectable, Late-stage disease, Recurrent, Second-line therapy or greater) in Japan (IV, Infusion)
- 10 Sep 2018 Takara Bio completes a phase I trial in Gastrointestinal cancer (Recurrent, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in Japan (IV) (UMIN000013378)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Inoperable/Unresectable, Late-stage disease, Recurrent, Second-line therapy or greater) in Japan (IV, Infusion)